- Home
- ITOS
as 08-15-2025 4:00pm EST
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 446.6M | IPO Year: | 2020 |
| Target Price: | $10.40 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Hold | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.80 - $18.13 | Next Earning Date: | 08-06-2025 |
| Revenue: | N/A | Revenue Growth: | 177.89% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of iTeos Therapeutics Inc. (ITOS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Detheux Michel | ITOS | Chief Executive Officer | Jun 9 '25 | Sell | $10.03 | 104,565 | $1,048,264.12 | 0 | |
| Detheux Michel | ITOS | Chief Executive Officer | Jun 4 '25 | Sell | $10.15 | 156,847 | $1,592,519.82 | 0 | |
| Hallal David | ITOS | Director | Jun 4 '25 | Sell | $10.15 | 114,682 | $1,164,404.66 | 0 |
Latest iTeos Therapeutics Inc. News
ITOS Breaking Stock News: Dive into ITOS Ticker-Specific Updates for Smart Investing
MT Newswires
2 months ago
ITeos Therapeutics Insider Sold Shares Worth $1,048,264, According to a Recent SEC Filing
MT Newswires
2 months ago
iTeos Therapeutics Insider Sold Shares Worth $1,592,520, According to a Recent SEC Filing
MT Newswires
2 months ago
iTeos Therapeutics Insider Sold Shares Worth $1,164,405, According to a Recent SEC Filing
Zacks
3 months ago
iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know
Pharmaceutical Technology
3 months ago
iTeos to shut down following $2bn GSK-partnered TIGIT asset failure
MT Newswires
3 months ago
Wedbush Downgrades iTeos Therapeutics to Neutral From Outperform, Adjusts Price Target to $12 From $10
MT Newswires
3 months ago
iTeos Therapeutics to Wind Down Operations
GlobeNewswire
3 months ago
iTeos Therapeutics Announces Its Intention to Wind Down Operations
Compare ITOS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ITOS iTeos Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.